| Bioactivity | Glycylglycylcysteine is a Thrombin Activatable Fibrinolysis Inhibitor (TAFI) inhibitor with a Ki of 0.99 μM and a IC50 of 9.4 μM in TAFI substrate assays. TAFI is a basic carboxypeptidase that functions as a fibrinolysis inhibitor through the cleavage of C-terminal lysine on partially degraded fibrin[1]. |
| Target | IC50: 9.4 μM (TAFI)Ki: 0.99 μM (TAFI) |
| Name | Glycylglycylcysteine |
| CAS | 95416-30-1 |
| Sequence | H-Gly-Gly-Cys-OH |
| Shortening | GGK |
| Formula | C7H13N3O4S |
| Molar Mass | 235.26 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Do YH, et al. Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives. Thromb Res. 2005;116(3):265-71. |
Glycylglycylcysteine
CAS: 95416-30-1 F: C7H13N3O4S W: 235.26
Glycylglycylcysteine is a Thrombin Activatable Fibrinolysis Inhibitor (TAFI) inhibitor with a Ki of 0.99 μM and a IC50
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.